尽管一项针对 Kenvue Inc 的诉讼裁决允许继续调查泰诺与神经发育障碍之间的潜在关联，这对公司而言无疑是个负面消息，但分析师认为，这不太可能危及金佰利（Kimberly-Clark）对其的收购计划。
法国巴黎银行分析师在报告中指出，他们维持对该股的中性评级。原因在于，若诉讼进一步推进并导致对 Kenvue Inc 不利的结果，公司可能面临重大的潜在负债风险。然而，他们也强调，新的研究支持了 Kenvue Inc 的观点，即对乙酰氨基酚（泰诺的主要成分）与神经发育障碍，尤其是注意缺陷多动障碍和自闭症之间，不存在因果关系。
分析师特别写道：“关键的是，我们并不认为今天的裁决会破坏金佰利的收购交易。”他们进一步指出，此次裁决并未对原告方专家证人主张存在关联的证词可靠性做出判断，而是认为这些问题应交由陪审团决定。
市场反应方面，Kenvue Inc 股价下跌1.8%，金佰利股价则下跌2.5%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.